Statements under the Private Securities Litigation Reform Act, as amended: With the exception of the historical information contained in this website, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually, mutually, or materially impact the matters herein described. These forward-looking statements include, but are not limited to: the ability to obtain regulatory approval for Vitaros^® in Europe and other markets in the time frames estimated, if at all; the ability to successfully develop other products in clinical development, including a room-temperature formulation of Vitaros^® and Femprox^®; our ability to enter into new licenses and partnering agreements; our ability to realize revenue under existing license agreements; and our ability to successfully commercialize Vitaros^®. Readers of these materials are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers of these materials are urged to read the risk factors set forth in the Company’s most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and its most recent SEC filings for additional risks and considerations that could cause actual results to differ materially from expected results. Company disclaims any intention to update this website to reflect actual subsequent events.